Drug
Tulmimetostat
Tulmimetostat is a pharmaceutical drug with 4 clinical trials. Currently 4 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
4(100%)
Phase Distribution
Ph phase_1
4
100%
Phase Distribution
4
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
4
trials recruiting
Total Trials
4
all time
Status Distribution
Active(4)
Detailed Status
Recruiting3
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
4
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Phase 14 (100.0%)
Trials by Status
recruiting375%
active_not_recruiting125%
Recent Activity
4 active trials
Showing 4 of 4
recruitingphase_1
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
NCT07190300
active_not_recruitingphase_1
Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome
NCT05944562
recruitingphase_1
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
NCT05467748
recruitingphase_1
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776
Clinical Trials (4)
Showing 4 of 4 trials
NCT07190300Phase 1
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
NCT05944562Phase 1
Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome
NCT05467748Phase 1
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
NCT04104776Phase 1
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4